BUZZ - Inovio Pharma shares soar after US Food and Drug Administration approves rare disease therapy
路透社2026/10/30 21:46October 30 - ** Inovio Pharmaceuticals (INO.O) shares surged 293.4% in after-hours trading to $2.36
** The U.S. Food and Drug Administration (FDA) approved (link) the company’s therapy for treating a rare respiratory disease, marketed under the brand name Voceryq
** Inovio’s therapy is approved for treating patients with recurrent respiratory papillomatosis, a condition that causes growths within the airways and typically requires repeated surgeries
** Inovio plans to commercialize the therapy independently in the U.S. and is working with Syneos Health to support its market launch
** As of the close of the previous trading day, the stock was down 65.4% year-to-date
(To facilitate non-native English speakers, Reuters automatically translates its reports into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation and provides it solely for readers’ convenience. Reuters accepts no responsibility for any harm or loss caused by use of the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The annualized deposit yield is 9.58%, Pendle launches its second ecosystem vault on Morpho.
France's fiscal outlook deteriorates as Fitch revises rating outlook to negative
Due to the deterioration of public finances, including slower growth, rising borrowing costs, and widening deficits, Fitch Ratings has revised France's credit rating outlook to negative.
Disciplined capital expenditure attracts market favor as Apple (AAPL.US) surpasses Nvidia (NVDA.US) to reclaim the top spot in global market capitalization
As concerns about Wall Street's massive returns on tech giants' artificial intelligence investments continue to intensify, Apple surpassed Nvidia on Friday to once again become the world's most valuable publicly traded company.
AI burning cash sparks credit risk concerns! S&P downgrades Meta (META.US) rating outlook to "negative," questioning its ability to monetize massive investments
S&P Global Ratings has revised Meta's credit rating outlook from “stable” to “negative,” citing the company's continued expansion of artificial intelligence (AI) capital expenditures, which has turned free cash flow negative. There remains uncertainty over whether these significant AI investments will generate sufficient returns in the coming years.
Crypto prices
More
